Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Shareholder suit against Johnson & Johnson, including CFO Caruso, may proceed; Novartis pauses OTC production at Nebraska plant; Mead Johnson finds Enfamil powder clear of bacteria after stores pull the product; John Gay leaves NPA after two years as executive director and CEO; more news In Brief.

Advertisement

Related Content

Omega Pharma Acquires Six Glaxo OTC Brands, But Alli Lingers
Omega Pharma Acquires Six Glaxo OTC Brands, But Alli Lingers
People In Brief
People In Brief
Tylenol Trickles Back To Shelves As J&J Touts Consumer Turnaround
Tylenol Trickles Back To Shelves As J&J Touts Consumer Turnaround
Novartis Opts For OTC Recall, With J&J/McNeil Lessons Still Fresh
J&J Wrongful Death Lawsuit Alleges Recalled Tylenol Link
J&J Directors Find Root Causes But Little Blame For OTC Quality Issues
NPA Chief Looks To Expand The Industry's "Toolbox For Advocacy"

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS105493

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel